Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

FDA Approves Sparsentan as First FSGS Treatment

FDA Approves Sparsentan as First FSGS Treatment
ShareXFacebook

(MedPage Today) -- The FDA expanded the indication of sparsentan (Filspari) to make it the first treatment for focal segmental glomerulosclerosis (FSGS), developer Travere Therapeutics announced on Monday. A once-daily oral tablet, sparsentan...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement